Filings

CTOR CITIUS ONCOLOGY, INC. 10-Q 2025-05-14

Item 1A. Risk Factors.

going concern and do not include any adjustments that might result from uncertainty about our ability to continue as a going

6 matches in this document

CTOR CITIUS ONCOLOGY, INC. 10-K 2025-12-23

Item 16. Form 10-K Summary.

going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has a working

7 matches in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-11-04

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-10-26

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 10-Q 2026-08-14

Item 6. Exhibits 29

report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;

5 matches in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-08-14

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-06-01

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-05-15

going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 10-Q 2026-05-15

Item 6. Exhibits 28

report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;

4 matches in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-05-06

going concern; the availability of future tranches under the Credit Facility and our ability to conduct future financings; our ability

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-04-29

going concern; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-03-31

going concern; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; early-stage

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-03-10

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-03-04

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2026-02-13

going concern; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 10-Q 2026-02-13

Item 6. Exhibits 23

report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;

4 matches in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2025-12-23

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2025-12-10

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2025-12-10

going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product

1 match in this document

CTOR CITIUS ONCOLOGY, INC. 8-K 2025-12-01

going concern ; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream ; physician and patient acceptance of LYMPHIR

1 match in this document